Baricitinib: Two Birds with One Stone

Saj, Fen; Kayal, Smita; Dubashi, Biswajit; Ganesan, Prasanth

doi:10.1007/s12288-022-01521-5

Cited by 1 publication

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 60 Some scientists recommended baricitinib over another JAK inhibitor, ruxolitinib for its abundant availability in low‐cost generic versions. 61 In terms of safety concerns, there is plenty of safety data. For example, Kalil et al 62 concluded remdesivir/baricitinib combined therapy is superior to remdesivir monotherapy in the case of hospitalized patients.…”

Section: Baricitinibmentioning

confidence: 99%

“…Therefore, in severe cases, the synergistic effect of this combination is reported to be beneficial in the management of cytokine storm, inflammation, SARS‐CoV‐2 replication, and viral load 60 . Some scientists recommended baricitinib over another JAK inhibitor, ruxolitinib for its abundant availability in low‐cost generic versions 61 . In terms of safety concerns, there is plenty of safety data.…”

Section: Baricitinibmentioning

confidence: 99%

See 1 more Smart Citation

Comparative evaluation of authorized drugs for treating Covid‐19 patients

Islam

Hasan

Rahman

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aims Vaccines are the first line of defense against coronavirus disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid‐19 pandemic. Here we aimed for a comparative evaluation of authorized drugs for treating Covid‐19 patients. Methods We searched in PubMed and Google Scholar using keywords and terms such as Covid, SARS‐CoV‐2, Coronavirus disease 2019, therapeutic management, hospitalized Covid‐19 patients, Covid‐19 treatment. We also gathered information from reputed newspapers, web portals, and websites. We thoroughly observed, screened, and included the studies relevant to our inclusion criteria. We included only the United States Food and Drug Administration (FDA) authorized drugs for this review. Results We found that molnupiravir and paxlovid are available for oral use, and remdesivir is for only hospitalized patients. Paxlovid is a combination of nirmatrelvir and ritonavir, nirmatrelvir is a protease inhibitor (ritonavir increases the concentration of nirmatrelvir), and the other two (remdesivir and molnupiravir) are nucleoside analog prodrugs. Remdesivir and molnupiravir doses do not need to adjust in renal and hepatic impairment. However, the paxlovid dose adjustment is required for mild to moderate renal or hepatic impaired patients. Also, the drug is not allowed for Covid‐19 patients with severe renal or hepatic impairment. Preliminary studies showed oral antiviral drugs significantly reduce hospitalization or death among mild to severe patients. Moreover, the US FDA has approved four monoclonal antibodies for Covid‐19 treatment. Studies suggest that these drugs would reduce the risk of hospitalization or severity of symptoms. World Health Organization strongly recommended the use of corticosteroids along with other antiviral drugs for severe or critically hospitalized patients. Conclusion All authorized drugs are effective in inhibiting viral replication for most SARS‐CoV‐2 variants. Therefore, along with vaccines, these drugs might potentially aid in fighting the Covid‐19 pandemic.

show abstract

Section: Baricitinibmentioning

confidence: 99%

Section: Baricitinibmentioning

confidence: 99%